BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 25398229)

  • 1. Relapses and disability accumulation in progressive multiple sclerosis.
    Paz Soldán MM; Novotna M; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Jan; 84(1):81-8. PubMed ID: 25398229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
    Ribbons KA; McElduff P; Boz C; Trojano M; Izquierdo G; Duquette P; Girard M; Grand'Maison F; Hupperts R; Grammond P; Oreja-Guevara C; Petersen T; Bergamaschi R; Giuliani G; Barnett M; van Pesch V; Amato MP; Iuliano G; Fiol M; Slee M; Verheul F; Cristiano E; Fernandez-Bolanos R; Saladino ML; Rio ME; Cabrera-Gomez J; Butzkueven H; van Munster E; Den Braber-Moerland L; La Spitaleri D; Lugaresi A; Shaygannejad V; Gray O; Deri N; Alroughani R; Lechner-Scott J
    PLoS One; 2015; 10(6):e0122686. PubMed ID: 26046348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term disability progression of pediatric-onset multiple sclerosis.
    McKay KA; Hillert J; Manouchehrinia A
    Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
    Ramsaransing GS; De Keyser J
    Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J; Kostic J; Mesaros S; Dujmovic Basuroski I; Stojsavljevic N; Kisic-Tepavcevic D; Pekmezovic T
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.